{"url_path":"/sec/nxtc/8-k/2026-07-14/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-14","source_url":"https://www.sec.gov/Archives/edgar/data/1661059/0001104659-26-083326-index.html","accession_number":"0001104659-26-083326","cik":"0001661059","ticker":"NXTC","issuer_name":"NextCure, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1661059/0001104659-26-083326-index.html","primary_entity_key":"0001661059","primary_entity_name":"NextCure, Inc."},"word_count":175,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits**\n\n \n\n(d) Exhibits\n\n \n\n**Exhibit No.**\n \n**Description**\n\n \n \n \n\n[2.1*](tm2620428d1_ex2-1.htm)\n \n[Agreement and Plan of Merger and Reorganization, dated as of July 14, 2026, by and among NextCure, Inc., Neptune Merger Sub Corp., Neptune Second Merger Sub, LLC and Avere Therapeutics, Inc.](tm2620428d1_ex2-1.htm)\n\n \n \n \n\n[10.1](tm2620428d1_ex10-1.htm)\n \n[Form of Avere Support Agreement](tm2620428d1_ex10-1.htm)\n\n \n \n \n\n[10.2](tm2620428d1_ex10-2.htm)\n \n[Form of NextCure Support Agreement](tm2620428d1_ex10-2.htm)\n\n \n \n \n\n[10.3](tm2620428d1_ex10-3.htm)\n \n[Form of Avere Securities Purchase Agreement](tm2620428d1_ex10-3.htm)\n\n \n \n \n\n[10.4](tm2620428d1_ex10-4.htm)\n \n[Form of Registration Rights Agreement](tm2620428d1_ex10-4.htm)\n\n \n \n \n\n[10.5](tm2620428d1_ex10-5.htm)\n \n[Form of Lock-Up Agreement](tm2620428d1_ex10-5.htm)\n\n \n \n \n\n[10.6](tm2620428d1_ex10-6.htm)\n \n[Form of CVR Agreement](tm2620428d1_ex10-6.htm)\n\n \n \n \n\n[99.1](tm2620428d1_ex99-1.htm)\n \n[Press Release, issued on July 14, 2026](tm2620428d1_ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (formatted as Inline XBRL)\n\n \n \n \n\n \n \n* Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.      \n\n \n\n \n\n \n\n** **\n\n**SIGNATURE**\n\n \n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\nDated: July 14, 2026\n**NEXTCURE, INC.**  \n\n \n \n \n\n \nBy:\n/s/ Steven P. Cobourn\n\n \nName:\nSteven P. Cobourn\n\n \nTitle:\nChief Financial Officer"}